ME Therapeutics

07/24/2026

Follow along with our summer series where we explore the concepts behind ME Therapeutics’s in vivo CAR therapy technology: what it is, what problems it solves, and what candidates are in our pipeline. This month: What is in vivo CAR?

07/15/2026

Here’s a closer look at our therapeutic mRNA candidate targeting the STING pathway. 🔽🔽

Tumors often hide from the immune system when STING is not sufficiently activated. Turning on STING is like flicking a switch to make “cold” tumors visible or “hot”.

Key findings from a colorectal cancer model:

– Our candidate led to the specific recruitment of immune cells into the tumor and significantly reduced tumor growth.

– A single dose synergized with a PD-1 checkpoint inhibitor that was ineffective on its own. This could mean our STING candidate may unlock the efficacy of checkpoint inhibitors in otherwise unresponsive tumours.

– Targeted delivery into myeloid cells in the tumor microenvironment may solve past roadblocks observed with drugs targeting STING, reducing systemic side effects.

Learn more: metherapeutics.com/programs/

06/24/2026

Coming to you from in San Diego, where we are feeling the momentum in the immuno-oncology space. It’s been a fantastic event so far, connecting with investors to discuss our differentiated science both in our in vivo CAR program and therapeutic mRNA program, along with our positive preclinical data.

If you are here at BIO and haven't connected with us yet, email [email protected].

06/17/2026

We are attending in San Diego and looking forward to meeting with investors.

Connect with us to learn more about our differentiated science that overcomes challenges in immuno-oncology, including the suppressive microenvironment of "cold" tumors and the lack of immune recognition of cancer.

- Our in vivo CAR program targets both CD19 and CD22 markers. Both assets that form the lead therapeutic candidate are currently, or have been, derisked in the clinic. We are also optimizing for both T cells and macrophages.

- Our therapeutic mRNA program activates the highly-validated STING immune pathway in the tumor microenvironment. Positive preclinical data has demonstrated a single dose of our lead candidate synergizes with a PD-1 checkpoint inhibitor otherwise ineffective on its own.

To schedule a meeting, email [email protected].

06/04/2026

CSE - Canadian Securities Exchange recently sat down with our CEO Salim Dhanji, Ph.D., for their Issuer Update.

Salim explains how ME Therapeutics is advancing cancer therapeutics that would re-engineer a patient’s immune cells in their body. This includes:
- our in vivo CAR program to directly recognize a patient’s cancer cells.
- our therapeutic mRNA program targeting the STING pathway to overcome a suppressive tumour environment and allow a pre-existing immune response to kick in.

Watch the full conversation on LinkedIn.

🧬 On the latest CSE Issuer Update, Salim Dhanji, Co-Founder and CEO of ME Therapeutics Holdings Inc. (CSE: METX), discusses the company's efforts to develop next-generation cancer therapies that work by re-engineering a patient's immune system directly within the body. The company's immuno-oncolo...

06/03/2026

We are pleased to announce a non-brokered private placement financing.

🔗 Read the release:
https://metherapeutics.com/me-therapeutics-announces-private-placement/

05/26/2026

“One of the things we are working on is very specific delivery of nucleic acids to the tumor microenvironment so we can specifically target immune cells and create a stronger anti-cancer immune response. On top of that, if you can reprogram immune cells to actually recognize the cancer, you can hit the cancer from both sides.”

In the latest episode of Stories in Life Sciences Podcast, ME Therapeutics CEO Dr. Salim Dhanji sits down with Christopher Wilson to discuss the promise of in vivo CAR therapy, the company’s unique path to first-in-human trials, and what it takes to raise capital for biotech in Canada.

🎧 Listen to the full conversation via link in bio.

05/26/2026

“One of the things we are working on is very specific delivery of nucleic acids to the tumor microenvironment so we can specifically target immune cells and create a stronger anti-cancer immune response. On top of that, if you can reprogram immune cells to actually recognize the cancer, you can hit the cancer from both sides.”'

In the latest episode of Stories in Life Sciences Podcast, ME Therapeutics CEO Dr. Salim Dhanji sits down with Christopher Wilson to discuss the promise of in vivo CAR therapy, the company’s unique path to first-in-human trials, and what it takes to raise capital for biotech in Canada.

🎧 Listened to the full conversation here:

- Apple: https://bit.ly/42Vi841
- Spotify: https://bit.ly/49mm0yN
- YouTube: https://bit.ly/3Rl9I3p

05/21/2026

We are still buzzing from Web Summit Vancouver and presenting at the Canadian Security Exchange’s exclusive Capital Tech Connect event, alongside other CSE technology companies. ✨

ME Therapeutics’s CEO Dr. Salim Dhanji spoke about how we are advancing the next generation of cancer medicines through approaches that overcome some of the biggest challenges in the field.

What an honour to share the momentum behind our in vivo CAR and therapeutic mRNA programs, while connecting with investors, founders, and industry leaders.

Web Summit